Godse Kiran V, Zawar Vijay, Krupashankar Ds, Girdhar Mukesh, Kandhari Sanjiv, Dhar Sandipan, Ghosh Sanjay, Rajagopalan Murlidhar, Zuberbier Torsten
Form the Shree Skin Centre & Pathology Laboratory, Nerul, Navi Mumbai, India.
Indian J Dermatol. 2011 Sep-Oct;56(5):485-9. doi: 10.4103/0019-5154.87119.
This consensus statement was developed by Special Interest Group - Urticaria (IADVL). Urticaria, a heterogeneous group of diseases, often cannot be recognized by its morphology. Due to non-specific and non-affordable diagnosis, management of urticaria, especially chronic urticaria, is very challenging. This guideline includes definition, causes, classification and management of urticaria. Urticaria has a profound impact on the quality of life and causes immense distress to patients, necessitating effective treatment. One approach to manage urticaria is identification and elimination of the underlying cause(s) and/or eliciting trigger(s), while the second one is treatment aimed at providing symptomatic relief. This guideline recommends use of second-generation non-sedating H1 antihistamines as the first-line treatment. The dose can be increased up to four times to meet the expected results. In case patients still do not respond, appropriate treatment options can be selected depending on the cost.
本共识声明由国际皮肤科联盟(IADVL)荨麻疹特别兴趣小组制定。荨麻疹是一组异质性疾病,通常无法通过其形态学特征来识别。由于诊断缺乏特异性且费用高昂,荨麻疹尤其是慢性荨麻疹的管理极具挑战性。本指南涵盖了荨麻疹的定义、病因、分类和管理。荨麻疹对生活质量有深远影响,给患者带来极大痛苦,因此需要有效治疗。管理荨麻疹的一种方法是识别并消除潜在病因和/或诱发因素,另一种方法是进行旨在缓解症状的治疗。本指南推荐使用第二代非镇静性H1抗组胺药作为一线治疗药物。剂量可增加至四倍以达到预期效果。如果患者仍无反应,可根据费用选择合适的治疗方案。